



December 3, 2014

Assembly Biosciences to Present at Investor Conferences

NEW YORK, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:ASMB) today announced that it is participating in two investor conferences this week. The company has been invited to join a Hepatitis B Virus panel at the 26th Annual Piper Jaffray Healthcare Conference being held at The New York Palace in New York City. The panel is scheduled at 10:00am ET today and will be co-moderated by Piper Jaffray analysts Josh Schimmer, MD and Ted Tenthoff.

Assembly management will also participate in the 2014 RBC Capital Markets' Healthcare Investor Day being held on December 4, 2014 at the JW Marriott in Denver, CO. The conference consists of one-on-one meetings with qualified institutional investors; no general corporate presentations are planned.

For more information about the Piper Jaffray Healthcare Conference, visit www.piperjaffray.com/2col.aspx?id=365.

For more information about the RBC Capital Markets' Healthcare Investor Day, visit www.rbccm.com/about/cid-202541.html, or contact the conference coordinator at (212) 437-9189.

About Assembly Biosciences

Assembly Biosciences, Inc. is a biopharmaceutical company developing novel therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's proprietary core protein allosteric modulators (CpAMs) are small molecule, oral agents for the treatment of viral infections. The company's lead program focuses on hepatitis B (HBV), which infects an estimated 350 million people worldwide and is associated with 600,000 deaths annually. CpAMs alter the HBV core protein, a unique target that is essential to the functioning of the virus. Unlike current therapies that only suppress HBV, CpAMs may have curative potential. Assembly is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as *C. difficile* infections. For more information, visit www.assemblybio.com.

CONTACT: Corporate:

Assembly Biosciences, Inc.

David Barrett

646-706-5208

dbarrett@assemblybio.com

Media:

BLL Partners LLC

Barbara Lindheim

212-584-2276

blindheim@bllbiopartners.com



Source: Assembly Biosciences

News Provided by Acquire Media